4 withdrawn, 2 completed, 2 terminated, 1 active not recruiting. 11 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Withdrawn 4, Completed 2, Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Warm Autoimmune Hemolytic Anemia: new trials by email Literature Review of Warm Autoimmune Hemolytic Anemia trials Research Report on Warm Autoimmune Hemolytic Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease CTX112 - Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 60 | 2026-07-17 | 2026-10-20 |
| Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab Ianalumab - Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2026-06-26 | 2026-10-15 | |
| Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA Zanubrutinib - Warm Autoimmune Hemolytic Anemia | Phase 2 | Unknown | Chen Miao | 22 | 2023-11-11 | 2024-04-26 |
| An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4) Povetacicept - Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia | Phase 1 / Phase 2 | Completed | Alpine Immune Sciences Inc, A Subsidiary of Vertex | 30 | 2023-07-03 | 2026-09-14 |
| Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia ALXN1830, Placebo - Warm Autoimmune Hemolytic Anemia | Phase 2 | Withdrawn | Alexion Pharmaceuticals, Inc. | 2022-01-01 | 2022-02-11 | |
| ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia ALXN1830, Placebo - Warm Autoimmune Hemolytic Anemia | Phase 2 | Withdrawn | Alexion Pharmaceuticals, Inc. | 2021-07-01 | 2020-07-13 | |
| To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA). RVT-1401 680 mg/weekly, RVT-1401 340 mg/weekly - Warm Autoimmune Hemolytic Anemia | Phase 2 | Terminated | Immunovant Sciences GmbH | 5 | 2020-08-11 | 2022-07-28 |
| Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia Ninlaro - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia | Phase 2 | Withdrawn | Assistance Publique - Hôpitaux de Paris | 2019-09-01 | 2019-10-28 | |
| Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia M281, Placebo - Warm Autoimmune Hemolytic Anemia | Phase 2 / Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 118 | 2019-08-15 | 2026-08-31 |
| A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) ALXN1830 - Warm Autoimmune Hemolytic Anemia | Phase 1 / Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 8 | 2018-01-10 | 2020-05-13 |
| Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) APL-2 - Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 24 | 2017-08-31 | 2024-12-12 |
Purpura, Thrombocytopenic, Idiopathic (4) · Anemia, Hemolytic, Autoimmune (2) · Anemia, Hemolytic (1) · Pathologic Complete Response (1)
Autoimmune Diseases (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Blood Coagulation Disorders (4) · Blood Platelet Disorders (4) · Cytopenia (4) · Hemorrhage (4) · Hemorrhagic Disorders (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Purpura (4) · Purpura, Thrombocytopenic (4) · Signs and Symptoms (4) · Skin Manifestations (4)
orilanolimab (3) · ianalumab (1) · ixazomib (1) · rhoA GTP-Binding Protein (1) · zanubrutinib (1)
Alexion Pharmaceuticals, Inc. (3) · Alpine Immune Sciences Inc, A Subsidiary of Vertex (1) · Apellis Pharmaceuticals, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · CRISPR Therapeutics AG (1) · Chen Miao (1) · Immunovant Sciences GmbH (1) · Janssen Research & Development, LLC (1) · Novartis Pharmaceuticals (1)
United States (8) · Spain (4) · Germany (3) · United Kingdom (3) · China (2) · France (2) · Israel (2) · Italy (2) · South Korea (2) · Australia (1) · Austria (1) · Brazil (1) · Canada (1) · Czechia (1) · Egypt (1)
Matthieu Mahevas (1)
PMID 33786812, PMID 39486046, PMID 42664110
2023 (2), 2018 (1), 2019 (1)